Brickell Biotech Inc (NASDAQ:BBI) Stock Sees Profit Booking At Higher Level

February 3, 2022

Clinical stage pharmaceutical firm Brickell Biotech Inc (NASDAQ:BBI) saw its stock correct quite sharply on Wednesday as it ended the day with a decline of 6% amidst a selloff. That being said, it is perhaps also important to keep in mind that over the course of the past week the stock is still up by as much as 12%. Trading Data On Wednesday, BBI stock fell 5.73% to $0.24 with…

Read More >>

Nasdaq Momentum Watchlist: BBI, QK, RETO, PT, CREX

January 19, 2022

Following were the most active stock buzzers on Monday. Keep an eye on these stocks this week. Nano-Cap Stocks Watchlist Viking Energy Group Inc. (OTCMKTS:VKIN) On a more speculative note, VKIN is a company to watch in the fast-growing ESG space.  VKIN’s patented ESG Clean Energy System creates clean electricity by capturing and repurposing carbon dioxide emissions from combustion engines.  The technology is useful for recycling operations, nitrogen removal, microgrids,…

Read More >>

Brickell Biotech Inc (NASDAQ:BBI) Stock Takes a Hit After New Stock Offerings

October 29, 2021

Clinical stage pharmaceutical firm Brickell Biotech Inc (NASDAQ:BBI) saw its stock tank by as much as 25% on Thursday after it made an announcement with regards to its underwritten public offering. The company announced the pricing of the previously announced offering yesterday and it seems that the details did not quite thrill investors. Market Action: On Thursday, BBI stock lost 25.53% at $0.3990 with more than 19.49 million shares, compared…

Read More >>

Brickell Biotech Inc. (NASDAQ:BBI) Stock Picks Up Momentum: Jumps 7% in a Week

September 2, 2021

Brickell Biotech Inc. (NASDAQ: BBI) jumped 7% in a week. The company and Voronoi Inc. have signed a definitive agreement with Voronoi Inc. for exclusive global rights to treatment developed from the novel DYRK1A inhibitor platform. Notably, the DYRK1A inhibitor platform seeks to restore the immune balance of individuals with dysregulated immune systems. As a result, the inhibitors offer potential in a wide range of inflammatory and autoimmune diseases. Brickell’s…

Read More >>